Applied Therapeutics Inc. (APLT)
Applied Therapeutics Statistics
Share Statistics
Applied Therapeutics has 116.36M shares outstanding. The number of shares has increased by 1.83% in one year.
| Shares Outstanding | 116.36M |
| Shares Change (YoY) | 1.83% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 111.03M |
| Failed to Deliver (FTD) Shares | 1.49K |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 16.42M, so 14.11% of the outstanding shares have been sold short.
| Short Interest | 16.42M |
| Short % of Shares Out | 14.11% |
| Short % of Float | 15.75% |
| Short Ratio (days to cover) | 11.19 |
Valuation Ratios
The PE ratio is -1.13 and the forward PE ratio is -0.76. Applied Therapeutics's PEG ratio is 0.02.
| PE Ratio | -1.13 |
| Forward PE | -0.76 |
| PS Ratio | 262.57 |
| Forward PS | 0.4 |
| PB Ratio | 2.1 |
| P/FCF Ratio | -1.42 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Applied Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.06 |
| Quick Ratio | 3.06 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $13K |
| Profits Per Employee | $-3.02M |
| Employee Count | 35 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -93.04% in the last 52 weeks. The beta is 1.89, so Applied Therapeutics's price volatility has been higher than the market average.
| Beta | 1.89 |
| 52-Week Price Change | -93.04% |
| 50-Day Moving Average | 0.5 |
| 200-Day Moving Average | 4.07 |
| Relative Strength Index (RSI) | 36.07 |
| Average Volume (20 Days) | 2.55M |
Income Statement
In the last 12 months, Applied Therapeutics had revenue of 455K and earned -105.62M in profits. Earnings per share was -0.76.
| Revenue | 455K |
| Gross Profit | 455K |
| Operating Income | -104.3M |
| Net Income | -105.62M |
| EBITDA | -104.3M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.76 |
Balance Sheet
The company has 79.4M in cash and 2.79M in debt, giving a net cash position of 76.6M.
| Cash & Cash Equivalents | 79.4M |
| Total Debt | 2.79M |
| Net Cash | 76.6M |
| Retained Earnings | -574.21M |
| Total Assets | 106.57M |
| Working Capital | 5.64M |
Cash Flow
In the last 12 months, operating cash flow was -84.31M and capital expenditures 0, giving a free cash flow of -84.31M.
| Operating Cash Flow | -84.31M |
| Capital Expenditures | 0 |
| Free Cash Flow | -84.31M |
| FCF Per Share | -0.6 |
Margins
Gross margin is 100%, with operating and profit margins of -22922.86% and -23214.07%.
| Gross Margin | 100% |
| Operating Margin | -22922.86% |
| Pretax Margin | -23214.07% |
| Profit Margin | -23214.07% |
| EBITDA Margin | -22922.86% |
| EBIT Margin | -22922.86% |
| FCF Margin | -18528.57% |
Dividends & Yields
APLT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for APLT is $5, which is 1415.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 1415.2% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -10.68 |
| Piotroski F-Score | 5 |